Celltrion Pharm셀트리온제약
068760 · KOSDAQ · ₩068760 · 셀트리온제약
₩36,800▼ ₩300 (0.81%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩536B | ₩478B | ₩389B | ₩386B | ₩399B |
| Cost of sales | ₩373B | ₩356B | ₩269B | ₩273B | ₩279B |
| Gross profit | ₩164B | ₩122B | ₩120B | ₩113B | ₩119B |
| Operating income | ₩56B | ₩37B | ₩36B | ₩38B | ₩48B |
| Net income | ₩39B | ₩22B | ₩21B | ₩26B | ₩35B |
| Net income to shareholders | ₩39B | ₩22B | ₩21B | ₩26B | ₩35B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩759B | ₩669B | ₩642B | ₩600B | ₩638B |
| Current assets | ₩471B | ₩392B | ₩365B | ₩312B | ₩331B |
| Cash and equivalents | ₩50B | ₩45B | ₩20B | ₩31B | ₩80B |
| Total liabilities | ₩323B | ₩273B | ₩265B | ₩243B | ₩306B |
| Current liabilities | ₩284B | ₩248B | ₩249B | ₩212B | ₩260B |
| Borrowings | ₩142B | ₩155B | ₩158B | ₩160B | ₩180B |
| Total equity | ₩436B | ₩397B | ₩377B | ₩357B | ₩332B |
| Shareholders' equity | ₩436B | ₩397B | ₩377B | ₩357B | ₩332B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩86B | ₩57B | ₩8.8B | −₩4B | ₩93B |
| Capital spending | ₩16B | ₩4.9B | ₩5B | ₩3.9B | ₩11B |
| Free cash flow | ₩70B | ₩52B | ₩3.8B | −₩7.9B | ₩82B |
Consolidated where available. Amounts in won.
Also known as: Celltrion Pharm / 셀트리온제약 / 068760 / KRX:068760
Source: KRX statistical information